The risks of overusing short-acting β2-agonists (SABA), including an increase in asthma-related deaths, are many and well known. The Global Initiative on Asthma (GINA) 2019 and 2020 updates recommend as-needed inhaled corticosteroid (ICS)/formoterol as the preferred rescue medication in mild asthma as monotherapy and also in moderate to severe asthma when the maintenance and reliever therapy (MART) strategy is used. Using SABA for symptom relief, however, was the standard of treatment for many years, and consequently this practice persists, particularly in patients not taking ICS regularly. Here, we examine the rationale for this shift from a long-standing recommendation for as-needed SABA treatment to the use of as-needed ICS/formoterol and consider clinical evidence on strategies for asthma treatment and patient management.

Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies / G.W. Canonica, P. Paggiaro, F. Blasi, A. Musarra, L. Richeldi, A. Rossi, A. Papi. - In: THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE. - ISSN 1753-4658. - 15(2021), pp. 17534666211042534.1-17534666211042534.6. [10.1177/17534666211042534]

Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies

F. Blasi;
2021

Abstract

The risks of overusing short-acting β2-agonists (SABA), including an increase in asthma-related deaths, are many and well known. The Global Initiative on Asthma (GINA) 2019 and 2020 updates recommend as-needed inhaled corticosteroid (ICS)/formoterol as the preferred rescue medication in mild asthma as monotherapy and also in moderate to severe asthma when the maintenance and reliever therapy (MART) strategy is used. Using SABA for symptom relief, however, was the standard of treatment for many years, and consequently this practice persists, particularly in patients not taking ICS regularly. Here, we examine the rationale for this shift from a long-standing recommendation for as-needed SABA treatment to the use of as-needed ICS/formoterol and consider clinical evidence on strategies for asthma treatment and patient management.
asthma; control; GINA; ICS/formoterol; SABA
Settore MED/10 - Malattie dell'Apparato Respiratorio
Article (author)
File in questo prodotto:
File Dimensione Formato  
Manifesto on the overuse of SABA in the management of asthma-new approaches and new strategies Ther Adv Resp Dis 2021.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 514.21 kB
Formato Adobe PDF
514.21 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/872916
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 2
social impact